[2023-2030] Antibody Library Technology Market Size & Share, Growth Outlook
The global antibody library technology market, valued at US$ 153.3 million in 2022, is expected to experience significant growth in the coming years, primarily driven by the escalating prevalence of chronic diseases and advancements in biotechnology. According to a recent report, the market size was estimated to be USD 145.71 million in 2021, with a projected compound annual growth rate (CAGR) of 4.76% during the forecast period 20232030. The rising demand for highly targeted therapies to treat a plethora of serious diseases, including cancer and other chronic disorders, is a key factor fueling the market's expansion.
For More Industry Insights Read: https://www.fairfieldmarketresearch.com/report/antibody-library-technology-market
The report highlights phage display and yeast display technologies as the market leaders in terms of revenue in 2021, with the drug discovery & development segment representing the largest application area. Moreover, biopharmaceutical companies were identified as the leading end-users in the same year.
The primary driver behind the growth of the global antibody library technology market is the increasing prevalence of chronic diseases worldwide, such as cancer. As these conditions continue to rise, there is a growing need for innovative and effective treatments. The antibody library market plays a crucial role in addressing this demand by providing a platform for the development of targeted therapies.
In addition, advancements in biotechnology and the pharmaceutical industry are instrumental in propelling the market's growth. The continuous development in biotechnology has led to the emergence of innovative technologies such as yeast and phage display, which are gaining traction due to their effectiveness in isolating and engineering antibodies. As these technologies evolve, they are expected to become even more pivotal in the development of therapeutics.
However, the market does face challenges, particularly the high cost of antibody therapies. The development and commercialization of these therapies require substantial investments,